Welcome to EQL Pharma's Investor Pages!

We strive to have an open and proactive dialogue with our shareholders.

64.00 SEK

To Stock Graph

+1.00 (+1.59%)

Nasdaq Stockholm

Annual Report 2023/2024Read Here

Interim Report Q2 2024/2025

Listen to CEO Axel Schörling present EQL Pharma's latest report.

Interim Report Q2 2024/2025

Press Releases

2024-11-15

EQL Pharma's CBDO increases his holding in the company

EQL Pharma's Chief Business Development Officer (CBDO), Carl Lindgren, increases his shareholding in the company. On November 14[th], Carl Lindgren has bought 10,000 shares in the Company at an ave...

2024-11-06

Interim Report April - September 2024

Regulatory

Sales and operating profit growth, new products added to the pipeline

2024-10-25

Invitation to presentation in connection with EQL Pharma's interim report, second quarter, 2024/25

EQL Pharma AB (publ) will publish its interim report for the second quarter, 2024/25, on Wednesday, November 6[th], before stock markets opening.

Se all

EQL Pharma in Short

EQL Pharma is an entrepreneurial pharmaceutical company focusing on simplicity and efficiency at all levels of the value chain in order to be able to deliver cost-efficient medicines of highest quality to pharmacies and hospitals.

Welcome to EQL Pharma's Investor Pages!

Interim Report Q2 2024/2025

Press Releases

EQL Pharma's CBDO increases his holding in the company

Interim Report April - September 2024

Invitation to presentation in connection with EQL Pharma's interim report, second quarter, 2024/25

EQL Pharma in Short

Financial Calendar

Reports

Subscribe